Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

[1]  C. R.J.,et al.  Statistics with Confidence (2nd ed.) , 2003 .

[2]  N. Guvener,et al.  Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity , 2002, Diabetes, obesity & metabolism.

[3]  E. Muls,et al.  The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study , 2001, International Journal of Obesity.

[4]  B. Kaplan-Machlis,et al.  Orlistat — A Novel Weight Loss Therapy , 2001, The Annals of pharmacotherapy.

[5]  S. O’Meara,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. , 2001, Health technology assessment.

[6]  P. Whiting,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. , 2001, Health technology assessment.

[7]  A. Astrup,et al.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial , 2000, The Lancet.

[8]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[9]  T. Wadden,et al.  Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. , 2000, Obesity research.

[10]  A. Scheen,et al.  Antiobesity pharmacotherapy in the management of Type 2 diabetes , 2000, Diabetes/metabolism research and reviews.

[11]  G. Williams,et al.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor , 2000, International Journal of Obesity.

[12]  M. Smithson.  Statistics with confidence , 2000 .

[13]  J. Rey,et al.  Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity , 1999, The Annals of pharmacotherapy.

[14]  Adesh K. Jain,et al.  Sibutramine produces dose-related weight loss. , 1999, Obesity research.

[15]  P. Vague,et al.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. , 1999, The American journal of medicine.

[16]  J. Zavoral.  Treatment with orlistat reduces cardiovascular risk in obese patients , 1998, Journal of hypertension.

[17]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[18]  L. V. Van Gaal,et al.  Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? , 1998, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[19]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[20]  L. V. Van Gaal,et al.  Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study , 1998, European Journal of Clinical Pharmacology.

[21]  P. Drouin,et al.  Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study , 1998, International Journal of Obesity.

[22]  J. Manson,et al.  A prospective study of body mass index, weight change, and risk of stroke in women. , 1997, JAMA.

[23]  M. Lean,et al.  Sibutramine--a review of clinical efficacy. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[24]  G. Bray,et al.  A double-blind randomized placebo-controlled trial of sibutramine. , 1996, Obesity research.

[25]  Turner Rc.  The role of obesity in diabetes , 1992 .

[26]  G A Colditz,et al.  Weight as a risk factor for clinical diabetes in women. , 1990, American journal of epidemiology.

[27]  U. Keil,et al.  WHO MONICA Project: risk factors. , 1989, International journal of epidemiology.

[28]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[29]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[30]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .